Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Nasopharyngeal Carcinoma 35Esophageal Squamous Cell Carcinoma 19Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Squamous Cell Carcinoma of Head and Neck 15Triple Negative Breast Neoplasms 14Breast Neoplasms 12Uterine Cervical Neoplasms 11Colorectal Neoplasms 11Small Cell Lung Carcinoma 10Melanoma 10Carcinoma, Renal Cell 9Stomach Neoplasms 8Recurrence 8Head and Neck Neoplasms 7Rectal Neoplasms 5Neoplasm Metastasis 5Esophageal Neoplasms 5Carcinoma, Transitional Cell 5Advanced Solid Tumor 5Urinary Bladder Neoplasms 4Sarcoma 4Pancreatic Neoplasms 4Neoplasms 4Liver Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Cholangiocarcinoma 4Solid Tumor 3Nasopharyngeal Neoplasms 3

Interventions

fludarabine phosphate 26Etoposide 23Peripheral Blood Stem Cell Transplantation 22pegaspargase 21Whole-Body Irradiation 21Mycophenolic Acid 20Cyclophosphamide 19Busulfan 17Gemcitabine 16Dexamethasone 16Tacrolimus 15Methotrexate 15Cyclosporine 12Radiotherapy 11Antilymphocyte Serum 11Melphalan 8Asparaginase 8Rituximab 7Oxaliplatin 7Flow Cytometry 6Therapeutics 5Lenalidomide 5Bortezomib 5thymoglobulin 4spartalizumab 4Transplantation 4Polymerase Chain Reaction 4Panobinostat 4Methylprednisolone 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Extranodal NK-T-Cell × toripalimab × Clear all
NCT04338282 2020-04-08

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡